Heterogeneous expression of α-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score

Histopathology

Volumn 50, Issue 2, 2007, Pages 243-251

  Murphy, A J ^a,b   Hughes, C A ^b   Lannigan, G ^a   Sheils, O ^b   O'Leary, J ^b   Loftus, B ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

methylacyl CoA racemase; Benign prostatic hyperplasia; Immunohistochemistry; P504S; Prostatic cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; STAINING;

HUMANS; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; SEVERITY OF ILLNESS INDEX;

EID: 33846016204     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02572.x     Document Type: Article

References (24)

1. Xu J, Stolk JA, Zhang X et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000; 60; 1677-1682.
2. Jiang Z, Woda BA, Rock KL et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 2001; 25; 1397-1404.
3. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002; 62; 2220-2226.
4. Rubin MA, Zhou M, Dhanasekaran SM et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287; 1662-1670.
5. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am. J. Surg. Pathol. 2003; 27; 1128-1133.
6. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumour marker overexpressed in several human cancers and their precursor lesions. Am. J. Surg. Pathol. 2002; 26; 926-931.
7. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am. J. Surg. Pathol. 2003; 27; 772-778.
8. Beach R, Gown AM, De Peralta-Venturina MN et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am. J. Surg. Pathol. 2002; 26; 1588-1596.
9. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum. Pathol. 2004; 35; 1462-1468.
10. Molinie V, Fromont G, Sibony M et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod. Pathol. 2004; 17; 1180-1190.
11. Yang XJ, Wu CL, Woda BA et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am. J. Surg. Pathol. 2002; 26; 921-925.
12. Leav I, McNeal JE, Ho SM, Jiang Z. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Hum. Pathol. 2003; 34; 228-233.
13. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum. Pathol. 2004; 35; 1272-1278.
14. Zhou M, Aydin H, Kanane H, Epstein JI. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am. J. Surg. Pathol. 2004; 28; 239-243.
15. Kuefer R, Varambally S, Zhou M et al. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumour differentiation. Am. J. Pathol. 2002; 161; 841-848.
16. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am. J. Clin. Pathol. 2003; 120; 737-745.
17. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J. Urol. 2004; 172; 1130-1133.
18. Rogers CG, Yan G, Zha S et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J. Urol. 2004; 172; 1501-1503.
19. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 2005; 63; 341-346.
20. Wu CL, Yang XJ, Tretiakova M et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum. Pathol. 2004; 35; 1008-1013.
21. Zitzelsberger H, Kulka U, Lehmann L et al. Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridisation. Virchows Arch. 1998; 433; 297-304.
22. Alers JC, Krijtenburg PJ, Vissers CJ, Bosman FT, van der Kwast TH, van Dekken H. Cytogenetic heterogeneity and histologic tumour growth patterns in prostatic cancer. Cytometry 1995; 21; 84-94.
23. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 2005; 47; 587-596.
24. Rubin MA, Bismar TA, Andren O et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol. Biomarkers Prev. 2005; 14; 1424-1432.